Product

Company

NCT01713335·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Institut National de la Santé Et de la Recherche Médicale, France

Age

50–75

Sex

ALL

Healthy volunteers

Accepted

Smoker with tobacco consumption of 20 pack/year
Normal lung function tests
Smoker with tobacco consumption of 20 pack/year
FEV1/FVC\<70% on lung function tests
no hospitalisation for exacerbation during 3 months before inclusion
Smoker with tobacco consumption of 20 pack/year
worsening of pulmonary symptoms
FEV1/FVC\<70% on lung function tests could be obtain before or 3 months after exacerbation

The record

StatusCompleted

PhaseNo phase

Taking part134

StartedOct 2012

UpdatedAug 26, 2021

Conditions

Where1

Clareo Health | Proteasis Evaluation in COPD